Document:

Exhibit
10.6

 

EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT

THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL

AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

MATERIAL
TRANSFER AGREEMENT

 

THIS
MATERIAL TRANSFER AGREEMENT (the “Agreement”) is made and entered into as of October 21, 2022 (the “Effective
Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit
Pennsylvania corporation, having an office at [***] (“RECIPIENT”) and AIM ImmunoTech Inc., having an address at 2117
SW Highway 484, Ocala, FL 34473 (the “PROVIDER”).

 

In
response to the RECIPIENT’s request for the transfer of Ampligen® (“Materials”), PROVIDER is willing to provide
such Materials, subject to the following terms and conditions:

 

	1.	Upon
    request for a specific quantity of Materials by RECIPIENT, such Materials shall be provided by PROVIDER to RECIPIENT, subject to
    availability of such Materials. The availability of such Materials shall be determined solely by PROVIDER.
	 	 
	2.	The
    Materials, and all unmodified derivatives or progeny of the Materials, remain the property of the PROVIDER. The Materials shall be
    used by RECIPIENT solely for pre-clinical research (Research Project) evaluating the effects of Ampligen on innate immune responses
    in the skin and in non-melanoma skin cancers as described in Exhibit A. The Materials, and any unmodified derivatives of the Materials,
    shall not be used: (a) in any product, (b) for the purpose of producing any product, or (c) for providing any service in which a
    product or service is sold or otherwise made commercially available. No other right or license, patent or otherwise, is granted to
    RECIPIENT for the use of the Materials as a result of PROVIDER’s transmission of them to RECIPIENT.
	 	 
	3.	The
    Materials shall not be sold, distributed or otherwise made available to any other party for any other purpose.
	 	 
	4.	The
    Materials shall be used with prudence and appropriate caution in any experimental work since not all of their characteristics are
    known. THEY ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS
    OR IMPLIED. PROVIDER MAKES NO WARRANTY OR CLAIM THAT THE MATERIALS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER PROPRIETARY
    RIGHTS. Except to the extent prohibited by law, RECIPIENT agrees to release the PROVIDER, its trustees, appointees, employees and
    agents from any liability in connection with use of the Materials by RECIPIENT. Except to the extent prohibited by law, RECIPIENT
    shall be liable for its acquisition, use, storage or disposal of the Materials by RECIPIENT.
	 	 
	5.	The
    Materials will be used in compliance with all applicable statutes and regulations, including NIH guidelines on the use of animals
    or recombinant DNA. The Materials [***].
	 	 
	6.	The
    parties shall provide to each other such Confidential Information as is reasonably necessary for purposes of the Research Project
    (Exhibit A).

 

    	 

     

    

 

EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT

THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL

AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

	7.	The
    parties will utilize the Confidential Information exchanged solely for the purposes of conducting the Research Project (Exhibit A).
	 	 
	8.	Pre-existing
    Property. RECIPIENT understands and acknowledges that Ampligen® (rintatolimod) is the property of PROVIDER and/or that it may
    be subject to certain intellectual property rights owned by or licensed to PROVIDER. All rights to Ampligen® (rintatolimod) belong
    to PROVIDER. This Agreement shall not be deemed or construed to convey, transfer, or license any of such intellectual property rights
    to RECIPIENT, other than the limited rights necessary to permit RECIPIENT to conduct the Research Project during the term of this
    Agreement. Further, all intellectual property belonging to either party prior to the execution of this Agreement (“Pre-existing
    Property) shall remain the separate property of that party and nothing contained in this Agreement shall be deemed to grant either
    directly or by implication, estoppel or otherwise any license under any patents, patent applications or other proprietary interests
    to Pre-existing Property of the other party.
	 	 
	9.	New
    Inventions. Ownership and rights to any new and patentable or unpatentable discovery, technology, know-how or other intellectual
    property arising from the performance of the Research Project (hereinafter “Inventions”) shall be governed by the following
    provisions: Other Inventions made solely by the Principal Investigator or employees of RECIPIENT shall be the property of RECIPIENT
    (hereinafter “RECIPIENT Inventions”); Other Inventions made jointly by employees or agents of PROVIDER and RECIPIENT
    shall be the joint property of PROVIDER and RECIPIENT (hereinafter “Joint Inventions”). Inventorship of Inventions conceived
    or reduced to practice in the course of performing the Research Project shall be determined by the application of U.S. patent laws.
	 	 
	10	This
    Agreement shall terminate upon completion of the Research Project or five (5) years from the Effective Date of this Agreement, whichever
    occurs first, unless terminated or extended through prior written agreement signed by authorized representatives of the parties.
    Either party may terminate this Agreement prior to the expiration of the designated term by giving sixty (60) days written notice
    to the other. The obligations of RECIPIENT hereunder shall survive termination. Upon termination, the Materials shall be either returned
    to PROVIDER or destroyed at the request of the PROVIDER.
	 	 
	11.	No
    Party will be liable to the other for any failure or delay in the performance of its obligations to the extent such failure or delay
    is caused by fire, flood, earthquakes, other elements of nature, acts of war, terrorism, riots, civil disorders, rebellions or revolutions,
    disease, epidemics, quarantines, pandemics, acts of government, a state of emergency, delays in visas, changes in laws and governmental
    policies, or other conditions beyond its reasonable control following execution of this Agreement. If the performance by either party
    of any of its obligations under this Agreement (including making a payment) is prevented by any such circumstances, then such party
    shall communicate the situation to the other as soon as possible, and the parties shall endeavor to limit the impact to the project.
    Nothing herein shall limit the rights of either party to terminate this Agreement.
	 	 
	12.	RESERVED

 

    	 

     

    

 

EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT

THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL

AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

	13.	[***].

	 	 
	14.	Notwithstanding
    anything to the contrary, this Agreement shall not be interpreted to prevent or delay publication of the Research Project results.
    RECIPIENT agrees to notify PROVIDER within a reasonable period, not less than thirty (30) days, prior to the submission for publication
    of the Research Project results or other disclosure of the results. PROVIDER is entitled to review such proposed publication or disclosure.
    RECIPIENT agrees to delete from any such proposed publication or disclosure any Confidential Information disclosed by PROVIDER to
    RECIPIENT, upon the reasonable request of PROVIDER. PROVIDER may request the reasonable delay of any such proposed publication or
    disclosure for an additional thirty (30) day period in order to file or have filed any patent applications on any inventions disclosed
    therein. RECIPIENT agrees to provide appropriate acknowledgement of the source of the material received under this Agreement in all
    publications.
	 	 
	15.
    	Governing
    Law. (a) The validity, interpretation, enforceability, and performance of this Agreement will be governed by and construed in
    accordance with the laws of Pennsylvania without regard to the application of conflict laws.
	 	 
	(b)	Any legal action or proceeding with respect to this Agreement may be brought in the courts of Pennsylvania, and by execution and delivery
of this Agreement, the parties agree to the jurisdiction of those courts.

  

	 	UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
	 	 		 	 
	 	By	/s/ Heide
    J. Eash	 	Date: October
    21, 2022
	 	Name:	Heide J. Eash 
	 	Title:	Associate Director of Fed. Contracts 
	 	 	 	 	 
	 	PROVIDER 	 	 
	 	 	 	 
	 	By	/s/ Peter
    W. Rodino	 	Date: October
    24, 2022
	 	 	Authorized Individual for the Provider 
	 	 	Printed Name: Peter W. Rodino, III 
	 	Title:	Chief Operating Officer

 

    	 

     

    

 

EXPLANATORY
NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT

THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL

AND (II) WOULD BE COMPETITIVELY
HARMFUL IF PUBLICLY DISCLOSED.

 

Exhibit
A

 

Delivery
of Ampligen [***]

 

[***]Exhibit
10.7

 

FOURTH
AMENDMENT TO AGREEMENT OF SALE AND PURCHASE

 

THIS
FOURTH AMENDMENT TO AGREEMENT OF SALE AND PURCHASE (this “Fourth Amendment”) is made as of October 21, 2022, by and
between AIM IMMUNOTECH INC., a Delaware corporation (“Seller”), ACELLORIES, INC., a New York corporation (“Original
Buyer”), and BH 783 JERSEY AVE, LLC, a New Jersey limited liability company (“New Buyer”).

 

WHEREAS,
Seller and Original Buyer have executed that certain Agreement of Sale and Purchase dated March 3, 2022, as amended by a First Amendment
to Agreement of Sale and Purchase dated June 27, 2022, a Second Amendment to Agreement of Sale and Purchase dated August 2, 2022 and
a Third Amendment to Agreement of Sale and Purchase dated August 31, 2022 (collectively, the “Purchase Agreement”)
for the purchase of certain Property, as defined in the Purchase Agreement, situate in the City of Brunswick, Middlesex County, New Jersey
and commonly known as 783 Jersey Avenue (“Property”); and

 

WHEREAS,
Seller, Original Buyer and New Buyer now desire to make certain amendments to the Purchase Agreement, upon and subject to the terms and
conditions of this Fourth Amendment.

 

NOW
THEREFORE, the parties hereto, in consideration of the mutual promises hereinafter set forth, and intending to be legally bound, hereby
agree as follows:

 

1.
New Buyer is hereby substituted for Original Buyer under the Purchase Agreement in all respects, and all references to “Buyer”
in the Purchase Agreement shall mean and refer to New Buyer.

 

2.
New Buyer acknowledges and reaffirms that it is purchasing the Property on a strictly “AS IS” basis as set forth in Section
11 of the Purchase Agreement.

 

3.
All capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement. This Fourth Amendment
may be signed in counterpart(s). For purposes of this Fourth Amendment, facsimile or electronic signatures shall constitute original
signatures. The transmission of a signed counterpart of this Fourth Amendment by electronic signature, facsimile or by portable document
file shall have the same force and effect as delivery of an original signed counterpart of this Fourth Amendment, and shall constitute
valid and effective delivery for all purposes. Except as expressly modified hereby, and in all respects, the remainder of the Purchase
Agreement is hereby ratified and shall continue in full force and effect without modification.

 

[Signatures
on Following Page]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Fourth Amendment to be duly executed as of the day and year first above written.

 

	 	Seller:
	 	 
	 	AIM
    IMMUNOTECH INC.
	 	 	 
	 	By:	 /s/
    Peter W. Rodino 
	 	Name:	Peter
    W. Rodino
	 	Title:	C.O.O.
	 	 	 
	 	Original
    Buyer:
	 	 
	 	ACELLORIES,
    INC.
	 	 	 
	 	By:	 /s/
    Albert Lalou 
	 	Name:	Albert
    Lalou
	 	Title:	V.P.
	 	 	 
	 	New
    Buyer:
	 	 
	 	BH
    783 JERSEY AVE, LLC
	 	 	 
	 	By:	 /s/
                                            Albert Lalou 

	 	Name:	Albert
    Lalou
	 	Title:	Managing
    Member

 

    	-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]